-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Assumes Vertex Pharmaceuticals at Buy, Lowers Price Target of $535

Benzinga·01/07/2026 13:42:19
語音播報
UBS analyst Michael Yee assumes Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy rating and lowers Price Target of $535.